| 2.41 -0.02 (-0.82%) | 04-24 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |   |
|||
| Targets | 6-month : | 3.19 | 1-year : | 3.73 |
| Resists | First : | 2.73 | Second : | 3.19 |
| Pivot price | 2.46 | |||
| Supports | First : | 2.25 | Second : | 1.95 |
| MAs | MA(5) : | 2.49 |
MA(20) : | 2.4 |
| MA(100) : | 1.94 |
MA(250) : | 1.91 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 43.9 |
D(3) : | 56 |
| RSI | RSI(14): 51.9 |
|||
| 52-week | High : | 3.4 | Low : | 0.97 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ ALEC ] has closed above bottom band by 35.5%. Bollinger Bands are 15% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 2.53 - 2.55 | 2.55 - 2.56 |
| Low: | 2.32 - 2.34 | 2.34 - 2.36 |
| Close: | 2.38 - 2.41 | 2.41 - 2.43 |
Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, a humanized recombinant monoclonal antibody, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease; and AL003, which is in Phase I clinical trial for the treatment of Alzheimer's disease. In addition, its products in development stage include AL044 that targets MS4A4A, a risk gene for Alzheimer's disease. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies, such as AL001 and AL101 to treat neurodegenerative diseases. The company was founded in 2013 and is headquartered in South San Francisco, California.
Sat, 25 Apr 2026
Alector (ALEC)'s technical outlook is bright after key golden cross - MSN
Sat, 25 Apr 2026
Alector gains as Cantor Fitzgerald upgrades on brain carrier platform - MSN
Thu, 23 Apr 2026
Alector (ALEC) Price Target Decreased by 42.61% to 2.24 - MSN
Tue, 21 Apr 2026
Alector (ALEC) Stock: Future Performance Expectations (Buying Pressure) 2026-04-20 - Elite Alerts - UBND thành phố Hải Phòng
Mon, 20 Apr 2026
Alector (ALEC) Stock: Why It Matters Now (Trades Higher) 2026-04-20 - Bearish Pattern - Xã Thanh Hà
Fri, 17 Apr 2026
Alector (ALEC) accounting officer sells 1,820 shares in 10b5-1 trade - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 110 (M) |
| Shares Float | 86 (M) |
| Held by Insiders | 10 (%) |
| Held by Institutions | 80.8 (%) |
| Shares Short | 6,280 (K) |
| Shares Short P.Month | 6,000 (K) |
| EPS | -1.39 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.28 |
| Profit Margin | 0 % |
| Operating Margin | -587.6 % |
| Return on Assets (ttm) | -25.2 % |
| Return on Equity (ttm) | -181.6 % |
| Qtrly Rev. Growth | -88.5 % |
| Gross Profit (p.s.) | -0.93 |
| Sales Per Share | 0.19 |
| EBITDA (p.s.) | -1.34 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -184 (M) |
| Levered Free Cash Flow | -114 (M) |
| PE Ratio | -1.74 |
| PEG Ratio | 0 |
| Price to Book value | 8.6 |
| Price to Sales | 12.63 |
| Price to Cash Flow | -1.45 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|